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Abstract
Background: In the EuroNet Pediatric Hodgkin Lymphoma (EuroNet-PHL) trials, deci-
sion onWaldeyer’s ring (WR) involvement is usually based on clinical assessment, that
is, physical examination and/or nasopharyngoscopy. However, clinical assessment only
evaluates mucosal surface and is prone to interobserver variability. Modern cross-
sectional imaging technology may provide valuable information beyond mucosal sur-
face, whichmay lead to amore accurateWR staging.
Patients, materials, andmethods: The EuroNet-PHL-C1 trial recruited 2102 patients,
of which 1752 underwent central review including reference reading of their cross-
sectional imaging data. In 14 of 1752 patients, WR was considered involved accord-
ing to clinical assessment. In these 14 patients, the WR was re-assessed by apply-
ing an imaging-based algorithm considering information from 18F-fluorodeoxyglucose
positronemission tomography, contrast-enhancedcomputed tomography, and/ormag-
netic resonance imaging. For verification purposes, the imaging-based algorithm was
applied to 100 consecutive patients whose WR was inconspicuous on clinical assess-
ment.
Results:The imaging-basedalgorithmconfirmedWR involvementonly in fourof the14
patients. Of the remaining 10 patients, four had retropharyngeal lymph node involve-
ment and six an inconspicuousWR. Applying the imaging-based algorithm to 100 con-
secutive patients with physiological appearance of their WR on clinical assessment,
absence of WR involvement could be confirmed in 99. However, suspicion of WR
involvement was raised in one patient.
Conclusions: The imaging-based algorithm was feasible and easily applicable at initial
staging of young patients with Hodgkin lymphoma. It increased the accuracy of WR
staging, whichmay contribute to amore individualized treatment in the future.
KEYWORDS
18F-FDG-PET, ENT investigation, MRI, multimodality imaging, CT, pediatric Hodgkin lymphoma,
staging,Waldeyer’s ring
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F IGURE 1 Anatomy of theWaldeyer’s ring. Illustrated by C.Mannewitz, Leipzig, Germany
1 BACKGROUND
Pediatric Hodgkin lymphoma (PHL) is highly curable by combined
modality treatment consisting of chemotherapy and radiotherapy.
However, radiotherapy is in particular responsible for treatment-
related late effects.1,2 Trials on PHL aim at individualized, risk-adapted
treatment to maintain high cure rates and to reduce late effects. The
worldwide largest trials in young Hodgkin lymphoma (HL) patients
were initiated by the North American Children’s Oncology Group and
the European Pediatric Hodgkin Lymphoma Group.3,4 Both groups
work closely together to reach harmonization in staging and response
assessment.5
The Waldeyer’s ring (WR) is an independent lymphatic region and
rarely involved in HL.6,7 An illustration of theWR anatomy is shown in
Figure 1. In the original Ann Arbor classification, introduced at a time
where imaging modalities were limited and therapy relied to a large
part on now outdated radiotherapy techniques, the WR also included
adjacent lymph nodes of the para- and retropharyngeal space.
In the North American Children’s Oncology Group HL trials, the
staging procedure of WR is not defined. In the European Network
for Pediatric Hodgkin Lymphoma (EuroNet-PHL) trials, WR staging is
usually performed by clinical assessment, that is, physical examination
and/or nasopharyngoscopy.5
Clinical assessment obviously only assesses the appearance of the
mucosal surface and possibly a displacement of the WR but not the
three-dimensional involvement of deeper adjacent structures. Fur-
thermore, clinical findings used to conclude WR involvement are not
specific which makes clinical assessment prone to high interobserver
variability.8,9 Still, prior to the introduction of modern imaging tech-
nologies, clinical assessment was considered the staging method of
choice to evaluate the entire WR.10 However, cross-sectional imaging
technologies have improved much during the last 30 years and com-
puted tomography (CT), magnetic resonance imaging (MRI), and 18F-
flurorodeoxyglucose positron emission tomography (18F-FDG-PET)
are widely available nowadays. Thus, it seems reasonable to include
these modalities into the staging procedure and to assess their perfor-
mance for amore adequate assessment ofWR involvement.9
Adequate WR staging is especially important when radiotherapy
is employed in the treatment protocol, that is, involved field radio-
therapy (IFRT). Since the WR covers a large area of the hypo-, oro-
, and nasopharynx, IFRT my consecutively lead to a large irradiation
field.11,12
The aim of this studywas to evaluate the potential of morphological
and metabolic cross-sectional imaging data for improving WR assess-
ment.
2 PATIENTS, MATERIALS, AND METHODS
Patient and imaging data analyzed in the present study are derived
from the EuroNet-PHL-C1 trial (EudraCT: 2006-000995-33;
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Clinicaltrial.gov: NCT00433459). This trial was initiated by the
European Network for Pediatric Hodgkin Lymphoma (EuroNet-PHL).
It recruited 2102 PHL patients (Classical HL) between 2007 and 2013.
1752 of the 2102 trial patients underwent the entire central review
process including reference evaluation of their original cross-sectional
imaging data in a standardized and structured manner.4 For initial
staging and early response assessment, 18F-FDG-PET and contrast-
enhanced CT (ceCT) from the upper neck to the upper thighs or, as
an alternative, MRI of neck, abdomen, and pelvis as well as ceCT of
the thorax were recommended. Data from all scans were stored on a
highly secured server with all necessary software for image analyses
provided.13
In central review, all lymphatic regions were assessed by cross-
sectional imaging including volumetric measurements at initial stag-
ing and restaging. Since WR involvement was considered a “non-
measurable” lymphatic region, WR evaluation at staging and restaging
was usually based on clinical assessment, performed by the local pedi-
atric oncologist or— preferentially — by an ear-nose-throat (ENT) spe-
cialist. No criteria were prespecified in the protocol for WR involve-
ment and biopsy was not required. The results of clinical assessment
were reported by the local department to the EuroNet study office and
documented by central data management, respectively.
Independent of stage, all patients received two cycles of OEPA (vin-
cristine, etoposide, prednisone, doxorubicin) induction chemotherapy.3
Patients with intermediate and high risk received two or four addi-
tional cycles, respectively, being randomly assigned to either COPP
(cyclophosphamide, vincristine, procarbazine, prednisone) orCOPDAC
(cyclophosphamide, vincristine, prednisone, dacarbazine).3 IFRT to all
initially involved sites (except for bone marrow lesions) was given
to patients with 18F-FDG-PET positive disease after two courses of
OEPA.3 18F-FDG-PET positivity was defined according to the criteria
released by the International Harmonization Project in Lymphoma.14
According to national legislation, the EuroNet-PHL-C1 trial was
approved by ethics committees, medical agencies, and institutional
review boards of the participating countries and centers. All patients
and/or their guardians gavewritten informedconsent. The institutional
review board of the EuroNet-PHL-C1 trial approved this retrospec-
tive imaging data analysis and waived the requirement for additional
informed consent.
The study presented here consists of three parts and described in
detail as follows:
(1) Construction of an imaging-based algorithm to systematically
evaluate theWR
The imaging-based algorithmwas createdon thebasis of specialized
knowledge gained throughmore than 10 years of cross-sectional imag-
ing data reference reading in PHL (LK and DiS), and evidence from the
literature. 8,9,15,16,17,18,19
The imaging-based algorithm included four steps:
First, 18F-FDG-PETat stagingwasusedas a screening tool. The com-
ponents of theWRwere checked visually for aspects of asymmetry, for
example, side differences in the configuration and/or differences in the
18F-FDG uptake characteristics of the pharyngeal and/or palatine ton-
sils. According to a systematic review by Guimaraes et al, asymmetry
was the most frequent sign of tonsillar lymphoma involvement.8 Com-
pleting this step, the WR was assigned to either category “symmetric”
or “asymmetric.”
Second, theWRwas evaluated morphologically on ceCT and/orMR
images, either confirming or rebuting the assignment based on 18F-
FDG-PET. If asymmetry was confirmed, ceCT and/or MR images were
checked for alternative explanations beyondWR involvement.
Third, based on the results of steps (i) and (ii), the WR was
categorized to be either involved (asymmetric WR on 18F-FDG-
PET and confirmation of WR involvement on ceCT and/or MRI)
or not involved (missing asymmetry on 18F-FDG-PET or asymme-
try on 18F-FDG-PET but alternative morphological explanation for
asymmetry).
For the fourth step, both metabolic and morphologic responses
after two courses of OEPA were compared for both the WR area and
the largest cervical lymphoma manifestation. Using the cervical lym-
phoma manifestation as a reference, cases were categorized based
on the response of WR structures as having either a lymphoma-like
response or a no-lymphoma-like response. Lymphoma-like response
was only concluded if metabolic and morphologic responses of the
WR area were similar to metabolic as well as morphologic response
of the largest cervical lymphoma manifestation. Otherwise, a no-
lymphoma-like response was determined, potentially attributable to
upper respiratory tract infection or inflammation. The latter two
are frequently found in young patients both before and during HL
treatment.9
(2) Application of the imaging-based algorithm to patients with WR
involvement according to clinical assessment
Patients considered for this analysis met the following criteria:
(i) Enrollment in the EuroNet-PHL-C1 trial.
(ii) WR involvement was detected by clinical assessment.
(iii) Central review including the original cross-sectional imaging data
was performed.
(iv) Cross-sectional imaging data were still available on the central
study server.
(v) Quality of cross-sectional imaging allowed sufficient re-
evaluation.
(3) Application of the imaging-based algorithm to patients without
WR involvement according to clinical assessment
Each patient of the EuroNet-PHL-C1 trial was registered with
a unique study identification number. Numbering either started
with 2000 and ended at 3799 or started with 5000 and ended
at 5400 (patients from Great Britain), respectively. The imaging-
based algorithm was applied to 100 consecutive patients starting at
study identification number 2001. They had to fulfill the following
criteria:
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TABLE 1 Characteristics of patients in whomWR involvement was determined by clinical assessment
Age Mean, Range 11 years, 3–16 years
Sex Female, Male n= 6, n= 8
Histology Mixed cellularity, Nodular sclerosis, No information n= 7, n= 6, n= 1
AnnArbor stage IIA, IIB, IIIA, IIIB, IIIAE, IVAE, IVBE n= 6, n= 1, n= 2, n= 2, n= 1, n= 1, n= 1
(i) Enrollment in the EuroNet-PHL-C1 trial.
(ii) WRwas assessed as uninvolved by clinical assessment.
(iii) Central review including the original cross-sectional imaging data
was performed.
(iv) Lymphoma lesions were detectable on at least one side of the
upper neck (i.e., lymph node levels I-III and V).20
(v) Cross-sectional imaging data were still available on the central
study server.
(vi) Quality of cross-sectional imaging data allowed sufficient re-
evaluation.
Relevant patient information (age, sex, histology, stage, early
response in 18F-FDG-PET response) for parts (2) and (3) of this study
was retrieved from the central database of the EuroNet-PHL-C1 study.
3 RESULTS
(1) Patients withWR involvement according to clinical assessment
(a) Patient selection and characterization
Twenty-eight of 2102 (1.3%) EuroNet-PHL-C1 trial patients had
documented involvement of the WR. Seventeen of 28 patients under-
went central review including their cross-sectional imaging data. In 14
of the 17 patients, WR involvement was determined by clinical assess-
ment. Characteristics of these 14 patients are shown in Table 1.
In three of the 17 patients,WR involvementwas determined only by
cross-sectional imaging data, whereas clinical assessment was either
not performed or negative. These patients were excluded from anal-
yses. However, detailed case descriptions are provided in the supple-
ment.
Figure 2 displays stepwise patient selection.
(b) Structured image analysis
Figure 3 shows the results after applying the imaging-based algo-
rithm to the 14 EuroNet-PHL-C1 patients assigned to have WR
involvement according to clinical assessment.
In eight of 14 patients, theWR showed asymmetric aspects on 18F-
FDG-PET, which were confirmed by ceCT and/orMRI.
In four of these eight patients, asymmetry was due to a well-
delimitable retropharyngeal lymph node adjacent to theWR (Figure 4).
Following two cycles of OEPA, these lymph nodes had either disap-
peared or markedly shrunken in size and metabolism had markedly
decreased, consistent with a lymphoma-like response.
F IGURE 2 Consort flow chart: Selection of patients whowere
determined to haveWR involvement according to clinical assessment
andwho underwent central review
In the other four patients, asymmetry on 18F-FDG-PET images
could not be explained by anything else than throughWR involvement
(Figure 5 ). The metabolically active mass was located in one of the
anatomic components of the WR and other reasons for asymmetry
could be excluded by ceCT and/or MRI. After induction chemother-
apy, asymmetry disappeared completely (Figure 5). Comparing both
metabolical andmorphological responses of the involvedWRareawith
the corresponding responses of the largest cervical lymphoma lesion
resulted in a lymphoma-like response in all four cases.
In six of 14 patients the WR showed a symmetric pattern without
any sign of lymphoma, neither on 18F-FDG-PET nor on ceCT and/or
MR images. In five of these six patients, the WRs responded morpho-
logically and metabolically differently compared to the largest cervi-
cal lymphoma lesion, consistent with a no-lymphoma-like response.
Together with the symmetric pattern at staging, the absence of a
lymphoma-like response made WR involvement unlikely. However, in
one patient the response of the WR to induction chemotherapy was
similar to the response of the largest cervical lymphoma lesion, result-
ing in a lymphoma-like response according to our definition. In this
case, the unlikely diagnosis of a diffuse, superficial infiltration by HL
could not be ruled out completely by image analysis.
In summary, the applied imaging-based algorithm confirmed WR
involvement in only four of the 14 cases. In the majority of cases,
however, the imaging-based algorithm led to a different conclusion
compared to the clinical assessment. In concrete terms, retropharyn-
geal lymph node involvement was diagnosed in four cases instead
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F IGURE 3 Flow chart with results from image analysis of patients withWR involvement according to clinical assessment
F IGURE 4 Patient with asymmetricWaldeyer’s ring on 18F-FDG-PET imaging (A) explainable on CT andMR images by a retropharyngeal
lymph node directly adjacent to the right palatine tonsil (B and C)
of WR involvement, and in five cases there was no evidence of
eitherWR or retropharyngeal lymph node involvement. Only one case
remained somewhat unclear due to its lymphoma-like response to
chemotherapy.
(2) Structured image analysis in patients without WR involvement
on clinical assessment
The structured image analysis was applied to 100 consecutive
patients without any sign of WR involvement according to clinical
assessment. Respective patient data are shown in Table 2, and results
of the structured image analysis are shown in Figure 6.
17 of the 100 consecutive patients showed asymmetric 18F-FDG
uptake pattern of their WR. In 14 of 17 patients, asymmetry could
also be confirmed on ce/CT and/or MRI. However, 13 had reasonable
explanations beyond HL involvement of the WR, like retropharyngeal
lymph nodes (n= 9), concomitant ENT infections, for example, by signs
of sinusitis (n = 3), or displacement of WR components by an airway
device (n = 1). Only in one patient a morphological correlate within
the pharyngeal tonsil was detectable which appeared irregular, was
difficult to delineate, and had a very strong contrast enhancement in
ceCT. These features made the lesion highly suspicious ofWR involve-
ment. In five of 14 patients, the WR or the lesions responsible for
asymmetry showed a lymphoma-like response (4× retropharyngeal
lymph node, 1× suspicion ofWR involvement), whereas no-lymphoma-
like response was determined in nine of 14 patients (5× retropharyn-
geal lymph nodes, 3× ENT infection, 1× airway device).
Three of 17 patients with asymmetric appearance of the WR on
18F-FDG had no morphologic correlate neither in the WR nor in
adjacent structures and showed a no-lymphoma-like response. Thus,
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F IGURE 5 Combined low-dose 18F-FDG-PET/CT images (A1, A2) andMR images (B1, B2) showWaldeyer’s ring involvement at initial staging
(A1, B1) and normalization following two courses of OEPA chemotherapy (A2, B2)
TABLE 2 Characteristics of patients in whomWR involvement was excluded by clinical assessment
Age Mean, Range 11.8 years, 3-17 years
Sex Female, Male n= 37, n= 63
Histology Mixed cellularity, Nodular sclerosis, Lymphocyte rich, No information n= 28, n= 56, n= 4, n= 12
AnnArbor stage IA, IIA, IIB, IIBE, IIIA, IIIB, IVA, IVB, IVBE n= 4, n= 42, n= 9, n= 5, n= 9, n= 9, n= 7, n= 11, n= 4
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F IGURE 6 Flow chart of the imaging-based algorithm applied to 100 patients withoutWaldeyer’s ring involvement according to clinical
assessment.WR,Waldeyer’s ring; RPLN, retropharyngeal lymph node
non-specific benign disorders like lymphoid hyperplasia were most
likely.
83 of the 100 patients showed a symmetric and homogeneous
uptake of their WR on 18F-FDG-PET images. Correspondingly, nei-
ther ceCT nor MRI showed any structural abnormalities. 28 of these
83 patients had a lymphoma-like response, whereas 55 showed a no-
lymphoma-like response.
4 DISCUSSION
About 1% of the patients enrolled into the EuroNet-PHL-C1 trial
had WR involvement which is compatible with other reports showing
that the WR is rarely involved by Hodgkin’s lymphoma.8,9 Neverthe-
less, precise staging of the WR including the differentiation between
directly adjacent lymph nodes and the WR is crucial when radiother-
apy is a component of the treatment. Currently, assessment of theWR
at staging in HL patients is commonly performed by clinical assess-
ment, sometimes involving a detailed examination by an ENT special-
ist. However, especially in the absence of biopsies, clinical assessment
remains highly subjective, and is therefore not recommendable as the
sole method of diagnosis.9
Therefore, an imaging-based algorithm was developed and retro-
spectively tested on two different cohorts of PHL patients treated in
the EuroNet-PHL-C1 trial. Building on the study results of Guimaraes
et al, symmetric versus asymmetric appearance of the WR was
chosen as the key criterion to decide on WR involvement and non-
involvement, respectively. Fromapathophysiological perspective,mor-
phological changes in tissues follow metabolic changes. Based on this
principle, 18F-FDG-PET images were used to sensitively screen for any
signs of asymmetry. However, in children and adolescents there is a
variety of non-malignant conditions, which may lead to either a homo-
geneously elevated or an asymmetric glucose uptake.9,10,17,19 In order
to gain specificity, 18F-FDG-PET resultswere further assessed by ceCT
and/or MRI. In addition, the WR and adjacent structures were com-
pared to chemotherapy response in nodal cervical HL lesions.
For the patients whose WR was evaluated as involved by clinical
assessment and who underwent central review (n = 14), we were able
to demonstrate that a structured analysis of modern imaging substan-
tially contributed to amore preciseWR staging.Most strikingly, in 29%
of these patients (n = 4), WR involvement was confirmed. In another
29%, clinical suspicion of WR involvement was well explainable by
involved retropharyngeal lymph nodes adjacent to the WR (n = 4).
Retropharyngeal lymph nodes occur in over 90%of all children and can
be a plausible reason for asymmetry.9,16 However, most retropharyn-
geal lymphnodesareof benignorigin.9,16 Todifferentiatebest between
retropharyngeal lymph nodes and lymphatic tissue of the WR, MRI
is preferable over ceCT because of a higher soft tissue contrast. The
remainingmore than40% (n=6) hadanentirely inconspicuous appear-
ance of the WR in both 18F-FDG-PET and ce/CT or MRI. This may be
due to the fact thatmucousmembrane alterations as evaluated by clin-
ical assessment are unspecific signs of a possible involvement, espe-
cially when diagnosed because of color alterations ormucosal lesions.8
In this respect, one could argue that superficial and diffuse lymphoma
infiltrations are not detectable on cross-sectional imaging and that
diffuse infiltrations may lead to an increased, yet homogenous and
symmetric glucose metabolism on 18F-FDG-PET images. Since asym-
metry in 18F-FDG uptake was a key criterion to prompt further struc-
tured analysis, such cases could be missed. However, as frequently
published, for example, for skeletal involvement, HL lesions are regu-
larly of focal and not diffuse appearance in 18F-FDG-PET.21,22 Further-
more, five of these six patients did not show 18F-FDG-PET response
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compatible with lymphoma manifestation when reanalyzed after two
cycles of chemotherapy. Thus, in only one patient the absolutely rare
constellation of a diffuse, superficial infiltration by HL could not be
ruled out completely by image analysis.
The proposed imaging-based algorithm was also tested for 100
patients who were negative for WR involvement on clinical assess-
ment. Seventeen of these 100 patients showed asymmetric patterns of
their WR region on 18F-FDG-PET images. The main reason for asym-
metry was a retropharyngeal lymph node (n = 9, 53%). Retropharyn-
geal lymph nodes are frequently found in children but are not neces-
sarily involved by lymphoma.9,16 Based on our algorithm, retropharyn-
geal lymph nodes were most likely involved in four patients as these
lymphnodeswere 18F-FDG-avid andmorphologically enlarged at stag-
ing and showed a lymphoma-like response following two courses of
chemotherapy. Other common reasons for asymmetry in this cohort
were non-specific benign disorders, for example, acute and chronic
ENT inflammation or lymphoid hyperplasia (n = 6, 35%). Guimaraes
et al reported on tonsillar asymmetry in children and adolescents.
According to their results tonsillar asymmetry was of non-specific ori-
gin in even 74% of the cases.17 Besides, it is also noteworthy that in
children who need narcosis to get their images performed, structures
of theWRcanbedisplacedby airwaydevices as detected in onepatient
of our cohort. This might be a source of misinterpretation when imag-
ing data are evaluated. Interestingly, in one of the 17 patients with
asymmetric WR appearance but negative clinical WR assessment, WR
involvementwas concludedon thebasis ofmorphological andmetabol-
ical images. This lesion also showed a lymphoma-like response fol-
lowing two courses of OEPA chemotherapy. 83 of 100 patients had
a symmetric appearance of their WR area both on 18F-FDG-PET and
on ceCT and/or MRI. In this patient group, WR response following
two courses of OEPA chemotherapy is of special interest: 28 of 83
patients (34%) showed a lymphoma-like response through neither clin-
ical assessment nor imaging data raised suspicion of WR involvement.
Thus, a lymphoma-like response is only informative in cases of clear
suspicion ofWR involvement or involved retropharyngeal lymphnodes
at initial staging.
The analysis of the two cohorts shows that the imaging-based algo-
rithm contributes to an accurate staging of the WR area. This is espe-
cially important in case of an indication for WR irradiation. The Ann
Arbor staging system defines theWR as a coherent site. Thus, in many
HL study protocols the WR is considered as one coherent site which
is treated in its entirety even if only one subsite is involved. However,
irradiation of the entire WR will affect many structures of the head
and neck like salivary glands, the thyroid and brain-supplying blood
vessels.23 This increases the risk of sicca syndrome, thyroid cancer,
hypothyroidism, or atherosclerosis in later life.1,7 Guidelines from the
International Lymphoma Radiation Oncology Group (ILROG) consider
eachof theWRsubsites as independent and recommend for aggressive
non-HLs of theWR not to irradiate the entireWR after chemotherapy
anymore.24 However, in the setting of combined modality treatment,
the optimal radiation volume for pediatric patients with HL remains
uncertain. Nevertheless, precise delineation of both WR and adjacent
lymph nodes before treatment is important for any rational reduction
in volumes especially when new irradiation technologies like proton
therapy are applied.25
Although this is a large and comprehensive analysis, there are lim-
itations: WR involvement determined by clinical assessment was re-
assessed by a dedicated imaging-based algorithm. None of the cases
confirmed by the imaging-based algorithm was confirmed by biopsy.
However, the introduction of WR biopsy would be much too invasive
and would delay treatment start. The added value of such a biopsy-
proven approach would be very limited with respect to event-free and
overall survival, given the extremely small rate ofWR involvement.
In summary, our analysis shows that the imaging-based algorithm
is at least as reliable as clinical assessment for detecting involvement
of WR in HL. In addition to this, the imaging-based algorithm is more
sensitive, as in the cohort of 100 consecutively chosen patients clini-
cal assessment is considered tohavenoWR involvement, the algorithm
detectedone casewith clear signs ofWR involvementon imaging.Most
importantly, the imaging-based algorithm is much more specific, as it
can differentiate between involvement of the WR itself, involvement
of retropharyngeal lymph nodes, and other not lymphoma-related rea-
sons, which might lead to a misdiagnosis ofWR involvement on clinical
assessment. This has significant consequences for therapy, especially
the extent of possible radiotherapy with its known potential long-term
adverse effects. Additionally, the imaging—the algorithm is based on—
is nowadays usually done routinely on initial staging, therefore replac-
ing determination of WR involvement by clinical assessment at initial
staging with the imaging-based algorithm will produce no extra costs
but will even save time and effort of both pediatricians and ENT spe-
cialists as well as patients necessary for clinical assessment of theWR.
Consequently, the imaging-based algorithmwill replace clinical assess-
ment for determination of WR involvement in future protocols of the
EuroNet-PHL consortium.
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